about
sameAs
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerMouse Models in Prostate Cancer Translational Research: From Xenograft to PDXUnderstanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practiceDocetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of LiteraturePatient experience in the treatment of metastatic castration-resistant prostate cancer: state of the scienceNon-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer MetabolismPersistent androgen receptor addiction in castration-resistant prostate cancerComparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trialsTargeting molecular resistance in castration-resistant prostate cancerAdaptive responses of androgen receptor signaling in castration-resistant prostate cancerODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerAndrogen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinasesTherapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancerHealth Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the LiteratureChemotherapy and its evolving role in the management of advanced prostate cancerHormone naïve prostate cancer: predicting and maximizing response intervalsTargeting the adaptive molecular landscape of castration-resistant prostate cancerPharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and EnzalutamideRadionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerChemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequencesEnzalutamide for the treatment of metastatic castration-resistant prostate cancer.Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trialsIs there a role for immune checkpoint blockade with ipilimumab in prostate cancer?Role of BioResponse 3,3'-Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience.Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancerSipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis.Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions.Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer.Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.Treatment sequencing in metastatic castrate-resistant prostate cancerRadium-223 in metastatic castration resistant prostate cancer.New developments in the treatment of castration resistant prostate cancer.Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer.Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
P921
Q26739708-D4C165E7-69CC-4033-9DF3-DAE6DA70DFF8Q26746524-16C94BEF-FD3A-4420-B001-163A34D7BA6DQ26748538-F8733970-7F1D-4A18-AEB1-78620C02F042Q26750735-8DFB45DE-8CE3-4F9A-9C19-81BCF9CBFA17Q26772883-2D8CA474-59B2-4B3B-89A1-0F0B527F5D7DQ26774456-437B1CC7-2F32-4721-A64E-D086C14FE8C8Q26777163-05193C27-5823-48CA-B7B6-E61926C2C4F7Q26785658-604BE8F2-BFA3-4D63-ADB1-8B15F02E2884Q26795445-4BA79A58-53AC-497F-9171-912DB9564FA7Q26795625-D7A2EB21-F871-4352-9ABD-933195374906Q26796568-6D548DB7-699A-4467-B6BA-62594EA73CA0Q26866135-70831B29-CEBA-4613-A11D-504C37C96233Q27002342-172FD0CF-27C9-4A8D-A208-9AF305EC3DE2Q27004566-F2AA86AA-D12D-4579-B942-3053F7757711Q27008883-9FFE2C77-5C49-49A3-8734-CA1AA83C7543Q27015904-3B5D9BFA-DCF7-486D-9860-55EC1C2AB7EBQ27022821-666C3247-813C-4580-8EA9-9D1CFA486CE9Q28076820-844432B6-69FC-4E56-B97D-D51354AE52C0Q28079918-44F8D39C-8B4C-4BD4-839A-72671E3D2668Q30245022-60E68EF7-1CB1-4115-ADD4-A60C13B575EEQ30248275-B648EEB2-41A5-4B92-B9E2-C7E4A5BE7CD4Q33621403-B125D843-7829-4C95-A66F-DF6266776DF3Q34283623-5A625384-344B-4B8A-B4E0-F8E33A7A335EQ34484835-4B84F6E5-F7F4-4493-A93A-2F05ADD084ABQ35213324-08D68A08-0844-47B3-9675-37189130F992Q35879087-BA4B38EB-F871-4166-95DB-7CEC04F1C103Q35881896-8C99EA85-A37D-4BEE-A2AA-E8348DD5464CQ36175852-9E0915E0-DA50-4455-B7D3-11E633AA691DQ36804897-A922AE50-06D4-4C34-BE12-F0DE90EEDD4AQ36844904-95747BCB-8063-4B5B-97C3-BAD881CFA14CQ37146546-C43D0CA3-0445-4D4E-A4CC-6DC0CDA5CD3CQ37531813-F5122FEF-9B05-4652-9B2A-1C8A277B03BBQ37538483-F2D7729A-9BD7-45F5-BDED-6CA67EF7458DQ38114780-39B0760A-DF8A-4006-BC0D-0D242867720AQ38131735-22C43337-F0E4-4261-B249-F67153246056Q38199939-181A223E-E2BE-49A6-86A5-958FB3EE82B9Q38203113-A0435614-AF93-496E-B7C0-DC22A20F4E03Q38206684-4B4D0722-F5FF-4D81-AA50-082F18020AA5Q38223782-C1125182-0C33-4FD2-A1D6-4CFA872338F0Q38276818-F50EA784-C740-4D9D-AD32-CA8273DF6C6F
P921
description
tumors or cancer of the prosta ...... hormones such as testosterone
@en
name
castration-resistant prostatic neoplasm
@en
tumeurs de la prostate résistantes à la castration
@fr
type
label
castration-resistant prostatic neoplasm
@en
tumeurs de la prostate résistantes à la castration
@fr
altLabel
castration-resistant prostatic neoplasms
@en
prostatic neoplasm, castration-resistant
@en
prefLabel
castration-resistant prostatic neoplasm
@en
tumeurs de la prostate résistantes à la castration
@fr
P672
P486
P31
P486
P672
C04.588.945.440.770.500
C12.294.260.750.500
C12.294.565.625.500
C12.758.409.750.500